InflaRx N.V. Presents COVID-19 Trial Synergy Data
Ticker: IFRX · Form: 6-K · Filed: May 21, 2024 · CIK: 1708688
Sentiment: neutral
Topics: clinical-trial, covid-19, drug-development, press-release
Related Tickers: IFRX
TL;DR
InflaRx N.V. (IFRX) shows vilobelimab might work better with other COVID drugs based on new PANAMO trial data.
AI Summary
On May 21, 2024, InflaRx N.V. announced new analysis from its PANAMO Phase III trial for severe COVID-19. The analysis suggests potential synergy between their drug vilobelimab and other immunomodulators, presented at ATS 2024.
Why It Matters
This analysis could impact the future development and potential efficacy of vilobelimab as a treatment for severe COVID-19, especially in combination therapies.
Risk Assessment
Risk Level: medium — The filing discusses trial data analysis, which is a step in drug development but does not guarantee regulatory approval or commercial success.
Key Players & Entities
- InflaRx N.V. (company) — Registrant
- vilobelimab (drug) — Investigational drug
- PANAMO Phase III trial (trial) — Clinical trial for severe COVID-19
- ATS 2024 (conference) — Event where data was presented
- May 21, 2024 (date) — Date of press release
FAQ
What specific immunomodulators were analyzed in combination with vilobelimab?
The filing does not specify which particular immunomodulators were analyzed in combination with vilobelimab, only that a potential synergy was observed.
When was the press release announcing this analysis issued?
The press release was issued on May 21, 2024.
What is the primary indication for the PANAMO Phase III trial?
The PANAMO Phase III trial is for severe COVID-19.
Where was the new analysis of the PANAMO trial presented?
The new analysis was presented at ATS 2024.
Does this filing include financial information or updates on regulatory status?
This filing is a Report of Foreign Private Issuer (6-K) and primarily includes a press release about clinical trial analysis; it does not appear to contain specific financial updates or regulatory status changes.
Filing Stats: 254 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-05-21 16:15:22
Filing Documents
- ea0206568-6k_inflarxnv.htm (6-K) — 15KB
- ea020656801ex99-1_inflarx.htm (EX-99.1) — 23KB
- ex9-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-045586.txt ( ) — 44KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: May 21, 2024 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer 3